All News

The FDA approved higher-dose semaglutide 7.2 mg (Wegovy HD), marking the fourth drug approved under the Commissioner's National Priority Voucher pilot program.

New studies link extreme heat, obesity coaching gaps, cancer delays, ACA cost spikes, and income inequality to widening global health disparities.

DLBCL is the most common subtype of non-Hodgkin lymphoma, known for its aggressiveness and heterogeneity. This presents treatment challenges if patients relapse following the initial chemoimmunotherapy regimen.

Women aged 35-60 years face higher cancer mortality than men in every generation since the 1930s due to breast and reproductive cancers.

Explore frequently asked questions on IPF therapies, including approved drugs, emerging treatments, and approaches to slow fibrosis.

Pediatric health coaching offers a workforce-driven solution to provide support that traditional care models often lack, with the potential to improve outcomes and reduce long-term costs.

Explore FAQs on AI in radiology, including malpractice risk, liability, and how juror perceptions shape legal outcomes when AI is involved.

Disparities in health system performance were larger by income in the US, indicating a need for structural and systemic policy efforts.

Expert guidance shows how to safely tailor aesthetic dermatology for allergic skin conditions like urticaria and eczema.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Rural US patients with breast cancer face higher advanced-stage diagnoses, with Black, Hispanic, uninsured patients and those in Southern regions at greatest risk.

Higher social vulnerability was associated with lower dietary fiber intake and a hostile gut microbiome in patients with melanoma or sarcoma receiving immune checkpoint blockade.

Rapid genetic test for IVF identifies FSHR variant in 60 minutes, guiding IVF hormone selection and improving in vitro fertilization success.

GLP-1s and SGLT2s were associated with improved kidney outcomes and no increased safety risks in patients with T1D and CKD.

A survey of marketplace enrollees revealed that they expect to cut back on basic household expenses to keep insurance coverage.

Male patients and those from minoritized racial and ethnic groups face longer times to treatment, especially in urban areas.

Patients with primary biliary cholangitis (PBC) can use linerixibat to address cholestatic pruritus, which up to 89% of patients with PBC experience.

A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and immunogenicity to reference ustekinumab in patients with moderate to severe plaque psoriasis.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

A new meta-analysis links menopausal hormone therapy to higher breast cancer risk with estrogen-progestin therapy, while estrogen-only therapy may lower risk.

New research shows that cardiovascular protection from GLP-1 receptor agonists such as semaglutide and tirzepatide diminishes within months of discontinuation.

Racial gaps in curative treatment for early-stage NSCLC persist among Medicare beneficiaries, with Black patients less likely to receive surgery.

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity.

Patients with multiple sclerosis valued both occupational therapy and physiotherapy as means of addressing their condition.

Study supports broader use of transient elastography to detect advanced liver fibrosis in patients with metabolic dysfunction–associated steatotic liver disease.

Icotrokinra is the first and only interleukin-23–targeted oral peptide approved for plaque psoriasis.